U.S. Cancer Centers Face Critical Drug Shortages

As of September 2026, U.S. cancer centers are grappling with an unprecedented crisis: a universal shortage of essential anticancer medications.

According to a recent survey by the National Comprehensive Cancer Network, every single responding cancer center is currently facing a deficit of at least one critical drug.

The impact on patient care is severe, with nearly 70% of hospitals forced to ration medications, lower doses, or delay treatment schedules.

Furthermore, the administrative burden of seeking new insurance authorizations for modified treatment plans is causing dangerous delays.

The root of the issue lies in a fragile pharmaceutical supply chain.

While hospitals are working to manage these gaps internally, experts argue that until structural policy reforms address manufacturing incentives and supply chain vulnerabilities, patients remain at risk of compromised care and higher rates of disease progression.